BRAF and metastatic melanoma: Although dabrafenib and vemurafenib are both promising and beneficial treatments in metastatic melanoma, their clinical responses differ according to the type of mutation present (V600K melanomas with brain metastases had a lower response rate of 7% to dabrafenib treatment compared to 39% with BRAF-V600E melanomas [101,103,104]).